Syndax Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Syndax Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical firm dedicated to developing advanced cancer treatments. The company’s portfolio features two key therapeutic candidates that have received FDA approval. Revuforj (revumenib), a selective menin inhibitor, is cleared for relapsed or refractory acute leukemias with KMT2A rearrangements and NPM1 mutations. Concurrently, Niktimvo (axatilimab), a monoclonal antibody that targets the CSF-1 receptor, is approved for treating chronic graft-versus-host disease in patients who have not responded to at least two prior systemic therapies. Both primary compounds are undergoing further clinical investigation for potential expansion into earlier treatment lines, combination regimens, and additional indications such as idiopathic pulmonary fibrosis. Syndax is also advancing Entinostat, a Class 1 HDAC inhibitor, in studies for various solid tumors and specific hematological malignancies. The company maintains strategic alliances, including a global collaboration with Incyte for axatilimab's development and commercialization, alongside other research partnerships. Incorporated in 2005, Syndax Pharmaceuticals is headquartered in Waltham, Massachusetts, concentrating on pioneering therapies to fulfill critical unmet medical requirements.
Company News
Syndax Announces Participation in September Investor Conferences
BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals Q2 Earnings Call Highlights
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript